Powerful bactericidal activity of moxifloxacin in human leprosy.
In a clinical trial of moxifloxacin in eight multibacillary leprosy patients, moxifloxacin proved highly effective. In all trial patients, a single 400-mg dose of moxifloxacin resulted in significant killing (P <or= 0.006) of Mycobacterium leprae, ranging from 82% to 99%, with a mean of 91%. In all instances, no viable bacilli were detected with an additional 3 weeks of daily therapy, this observed rapid bactericidal activity being matched previously only by rifampin. On moxifloxacin therapy, skin lesions cleared exceedingly rapidly with definite improvement observed consistently after eight doses and progressive resolution continuing for the 56 days of the trial. Side effects, toxicities, and laboratory abnormalities were mild, not requiring discontinuation of therapy.
Leonard Wood Memorial Center for Leprosy Research, Cebu, Philippines.
Fe Eleanor F
FE
Pardillo
Jasmin
J
Burgos
Tranquilino T
TT
Fajardo
Eduardo
E
Dela Cruz
Rodolfo M
RM
Abalos
Rose Maria D
RM
Paredes
Cora Evelyn S
CE
Andaya
Robert H
RH
Gelber
D000328:Adult; D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D001372:Aza Compounds / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D024841:Fluoroquinolones; D005528:Foot / Q000382:microbiology; D006801:Humans; D007918:Leprosy / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology; D008297:Male; D051379:Mice; D008875:Middle Aged; D000077266:Moxifloxacin; D009166:Mycobacterium leprae / Q000187:drug effects* / Q000254:growth & development / Q000472:pathogenicity; D011804:Quinolines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D012867:Skin / Q000382:microbiology / Q000473:pathology; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin